person · Reporting owner

Hagopian Henry III

Disclosed activity across 2 companies

Tapewire entity: 107992
SEC CIK: 0001821822

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Annovis Bio, Inc.ANVS · Entity 7001	Chief Financial Officer	November 20, 2023	November 22, 2023
Organogenesis Holdings Inc.ORGO · Entity 6275	Interim CFO	January 13, 2021	January 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Annovis Bio, Inc.

Report date November 20, 2023 · Filed November 22, 2023 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,820	Reported balance After 2023-11-20 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-11-20 · Grant · Acquired 820 · Balance 1,820

Organogenesis Holdings Inc.

Report date January 13, 2021 · Filed January 16, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	12,073	Reported balance After 2021-01-13 transaction · row 1 1 source row Row 1 · 2021-01-13 · Grant · Acquired 10,700 · Balance 12,073 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years from the date of grant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.34 · Expires 2031-01-13	Direct	64,198	Reported balance After 2021-01-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-01-13 · Grant · Acquired 64,198 · Balance 64,198 F2: The option becomes exercisable in equal yearly installments over four years from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years from the date of grant.

F2: The option becomes exercisable in equal yearly installments over four years from the date of grant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2023 Filed Nov 21, 2023 19:29 UTC	Annovis Bio, Inc. ANVS · Entity 7001	GrantCommon Stock	824	$6.07	$5,001.68	Disclosure SEC source: 0001104659-23-120301 · tm2331305-2_4seq1.xml · nonDerivative · entry 1 Hagopian Henry III · CIK 0001821822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,824 Read SEC document
November 20, 2023 Filed Nov 22, 2023 21:21 UTC Amendment	Annovis Bio, Inc. ANVS · Entity 7001	GrantCommon Stock	820	$6.10	$5,002.00	Disclosure SEC source: 0001104659-23-120760 · tm2331305d8_4a.xml · nonDerivative · entry 1 Hagopian Henry III · CIK 0001821822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,820 Read SEC document
April 07, 2023 Filed Apr 12, 2023 01:08 UTC	Annovis Bio, Inc. ANVS · Entity 7001	GrantCommon Stock	1,000	$12.61	$12,610.00	Disclosure SEC source: 0001104659-23-044206 · tm2312464-4_4seq.xml · nonDerivative · entry 1 Hagopian Henry III · CIK 0001821822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:42 UTC	Annovis Bio, Inc. ANVS · Entity 7001	GrantStock Option (right to buy) · Derivative	7,672	$0.00 Strike: $13.17	$0.00	Disclosure SEC source: 0001104659-23-005480 · tm234043-5_4seq1.xml · derivative · entry 1 Hagopian Henry III · CIK 0001821822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,672 Underlying: Common Stock · 7,672 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive quarterly installments of 1,918 shares each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025. Read SEC document
August 29, 2022 Filed Sep 1, 2022 00:14 UTC	Annovis Bio, Inc. ANVS · Entity 7001	GrantStock Option (right to buy) · Derivative	120,000	$0.00 Strike: $11.55	$0.00	Disclosure SEC source: 0001104659-22-096653 · tm2224852-2_4seq1.xml · derivative · entry 1 Hagopian Henry III · CIK 0001821822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-08-29 F1 · derivative.exercise_date: The stock option vests one-third on August 29, 2023 and the remaining two-thirds will vest in eight consecutive quarterly installments beginning the fifteenth month after August 29, 2022, and will vest in full upon a Change of Control (as defined in the Company's 2019 Equity Incentive Plan), with vesting conditioned on continued employment on the applicable vesting dates. Read SEC document
January 13, 2021 Filed Jan 16, 2021 01:34 UTC	Organogenesis Holdings Inc. ORGO · Entity 6275	GrantStock Option (Right to Buy) · Derivative	64,198	$0.00 Strike: $7.34	$0.00	Disclosure SEC source: 0001661181-21-000003 · edgar.xml · derivative · entry 2 Hagopian Henry III · CIK 0001821822 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,198 Underlying: Class A Common Stock · 64,198 shares Expires 2031-01-13 F2 · derivative.exercise_date: The option becomes exercisable in equal yearly installments over four years from the date of grant. Read SEC document
January 13, 2021 Filed Jan 16, 2021 01:34 UTC	Organogenesis Holdings Inc. ORGO · Entity 6275	GrantClass A Common Stock	10,700	$0.00	$0.00	Disclosure SEC source: 0001661181-21-000003 · edgar.xml · nonDerivative · entry 1 Hagopian Henry III · CIK 0001821822 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,073 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years from the date of grant. Read SEC document
August 21, 2020 Filed Aug 25, 2020 20:34 UTC	Organogenesis Holdings Inc. ORGO · Entity 6275	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001661181-20-000029 · edgar.xml · derivative · entry 1 Hagopian Henry III · CIK 0001821822 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2030-08-21 F1 · derivative.exercise_date: The option becomes exercisable in equal yearly installments over four years from the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.